Video

It's an Exciting Time for Mantle Cell Lymphoma

Author(s):

Michael Wang, M.D.

There are many exciting advances happening in the field of mantle cell lymphoma.

It is an exciting time for mantle cell lymphoma (MCL), with new treatments being explored that will lead to better patient outcomes, according to Michael Wang, M.D., professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center.

Progress is being made in targeted therapies, immunotherapy and cell therapies, according to Wang, who said that in his lifetime, there might be a percentage of patients who are cured of the disease.

Related Videos
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Image of a man wearing a black suit and tie.
Image of a man with white hair and a white goatee.
Image of a woman with brown wavy hair, wearing a navy blue top.
Image of a man wearing a suit with a red bowtie.
Image of a man with rectangular glasses and a goatee.
Image of a woman with glasses and dark hair.
Related Content
Picture of Dr. Guillermo Garcia-Manero
September 18th 2024

Why Transfusion Independence Matters for Patients With MDS

Alex Biese
An expert explained the burden that red blood cell transfusions can place on patients with MDS.
Image of "FDA Approved" in red.
September 6th 2024

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

Alex Biese
Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.
Illustration of a woman with long blonde hair, wearing sunglasses.
August 26th 2024

8 Things to Do While in the Hospital for Cancer Treatment

Mary Sansone
While spending weeks in the hospital for acute myeloid leukemia, I tried eight fun things to keep me busy.
Image of lymphoma cells.
July 24th 2024

CAR-T Cell Therapy for Relapsed, Refractory Mantle Cell Lymphoma Fills Unmet Need

Ashley Chan
Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.
Image of a man wearing a light blue polo shirt.
July 18th 2024

Radiation a Curative-Intent Option in NSCLC and Interstitial Lung Disease

Alex Biese
For some patients with early non-small cell lung cancer and lung scarring, stereotactic ablative radiotherapy may be a viable option, research has shown.
Finding a Second Opinion Was a Pivotal Moment in My Cancer Experience
July 18th 2024

Finding a Second Opinion Was a Pivotal Moment in My Cancer Experience

Jim Maloney
From second opinions to research and asking for help, here are some pivotal lessons I learned after a mantle cell lymphoma diagnosis.